Labetuzumab govitecan
As of the edition of 20 October 2026, Labetuzumab govitecan is an antibody drug conjugate: stopped in 2017; acts on CEACAM5 and TOP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Antibody drug conjugate
- Registered trials
- 3, 2 stopped early
- Disease areas
- Cancer; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 1 company-target row on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Labetuzumab govitecan.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company-target row is on route A because of Labetuzumab govitecan.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 2 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2011 to now |